How to Navigate the Road to 2030 in a Shifting Global Landscape

Enhance your progress and impact delivered in the first phase of the 2023–2030 strategy. You’ll walk away with a blueprint to: 

• Bolster how global policy and geopolitical shifts are influencing strategic direction.
• Leverage how to embed new forms of evidence in practice for HTA and access.
• Ensure you understand how evidence expectations are evolving across payers, regulators, and industry.
• Master what interested parties should anticipate from Canada’s Drug Agency through to 2030.

 Gain clarity on progress to date and how embedding new forms of evidence will redefine access and decision-making through 2030.